Search Medical Condition
Please enter condition
Please choose location from dropdown

Rugby, United Kingdom Clinical Trials

A listing of Rugby, United Kingdom clinical trials actively recruiting patients volunteers.

RESULTS

Found (40) clinical trials

Efficacy and Safety of Two Different Aflibercept Regimens in Subjects With Neovascular Age-related Macular Degeneration (nAMD)

330 Patients who have completed at least one year of treatment with aflibercept will be randomized to two different aflibercept regimens and followed for 76 weeks.

Phase

0.46 miles

Learn More »

Prospective Single-arm Multi Centre Observations Ultimaster Des Registry

All consecutive patients suitable for treatment with DES according to hospital routine practice in centres across the world that agree to participate in the e-ULTIMASTER registry will be treated with Ultimaster DES. Secondary objectives Evaluation of worldwide utilization of DES, Detection of rare events in representative patient population, identification of ...

Phase N/A

7.59 miles

Learn More »

PATH-2: Platelet Rich Plasma in Achilles Tendon Healing

PURPOSE The aim of this study is to evaluate the effectiveness of treating ruptured Achilles tendon with autologous platelet rich plasma. The investigators plan to compare the outcome of traditional methods of immobilisation in a cast with the outcome of the same methods after applying platelet rich plasma to the ...

Phase N/A

8.04 miles

Learn More »

Intensity-Modulated Radiation Therapy in Treating Patients With Localized Prostate Cancer

OBJECTIVES: - Determine the safety and efficacy of conventional vs hypofractionated high-dose intensity-modulated radiotherapy in patients with localized prostate cancer. - Determine the side effects of these regimens in these patients. - Determine whether hypofractionated radiotherapy schedules will improve the therapeutic ratio by either improving tumor control or reducing normal ...

Phase

8.3 miles

Learn More »

Tysabri Observational Program

TOP is an epidemiological observational study of participants receiving natalizumab, with each participant to be followed for up to 10 years. This study is designed to address the long-term safety profile and the long-term impact on disease activity and progression of natalizumab with marketed use, and the impact of treatment ...

Phase N/A

8.3 miles

Learn More »

Dalteparin in Preventing Blood Clots in Patients With Lung Cancer

OBJECTIVES: Primary - Determine whether the addition of dalteparin results in improved survival. Secondary - Determine venous thrombotic event-free survival and metastasis-free survival. - Determine serious adverse events in patients treated with this drug. - Determine the toxicity of this drug in these patients. - Determine the quality of life, ...

Phase

8.3 miles

Learn More »

Prostate Adenocarcinoma TransCutaneous Hormones

OBJECTIVES Primary Compare the progression-free survival and overall survival of patients with locally advanced or metastatic prostate cancer treated with transcutaneous estrogen patches vs luteinizing hormone-releasing hormone analogues. Secondary Compare the cardiovascular system-related morbidity and mortality in patients treated with these regimens Compare the activity of these treatments, in terms ...

Phase

8.3 miles

Learn More »

Study Evaluating CERAMENT |G in Open Diaphyseal Tibial Fractures

CERAMENT|G is a resorbable, gentamicin containing ceramic bone graft indicated to fill bony voids or gaps which are not intrinsic to the stability of the bony structure and where there is risk of bacterial contamination.

Phase N/A

8.3 miles

Learn More »

Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease

The purpose of the study is to assess the safety and efficacy of JNJ-64304500 in participants with moderately to severely active Crohn's disease.

Phase

8.3 miles

Learn More »

A Study of ASP2215 (Gilteritinib) Administered as Maintenance Therapy Following Induction/Consolidation Therapy for Subjects With FMS-like Tyrosine Kinase 3 (FLT3/ITD) Acute Myeloid Leukemia (AML) in First Complete Remission

Subjects in CR1 will be approached for this study after induction/consolidation therapy is complete and a decision not to proceed with transplantation is made or a suitable donor could not be identified. Subjects will be randomized in a 2:1 ratio to receive gilteritinib or placebo. Subjects will enter the screening ...

Phase

8.3 miles

Learn More »